Evidence map›Paper›PMID 37066278›Full record

ArticlebioRxiv : the preprint server for biology2023

Analysis of the Combined Effect of rs699 and rs5051 on Angiotensinogen Expression and Hypertension.

Nicholas R Powell, Tyler Shugg, Jacob Leighty, Matthew Martin, Rolf P Kreutz, Michael T Eadon, Dongbing Lai, Tao Lu, Todd C Skaar

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Nicholas R PowellIndiana University School of Medicine, Department of Medicine, Division of Clinical Pharmacology, Indianapolis IN.
Tyler ShuggIndiana University School of Medicine, Department of Medicine, Division of Clinical Pharmacology, Indianapolis IN.
Jacob LeightyIndiana University School of Medicine, Department of Medicine, Division of Clinical Pharmacology, Indianapolis IN.
Matthew MartinIndiana University School of Medicine, Department of Pharmacology and Toxicology, Indianapolis IN.
Rolf P KreutzIndiana University School of Medicine, Department of Cardiology, Krannert Institute of Cardiology, Indianapolis IN.
Michael T EadonIndiana University School of Medicine, Department of Medicine, Division of Nephrology, Indianapolis IN.
Dongbing LaiIndiana University School of Medicine, Department of Medical and Molecular Genetics, Indianapolis IN.
Tao LuIndiana University School of Medicine, Department of Pharmacology and Toxicology, Indianapolis IN.
Todd C SkaarIndiana University School of Medicine, Department of Medicine, Division of Clinical Pharmacology, Indianapolis IN.
Indiana University School of Medicine

Funding

Indiana University Comprehensive Training in Clinical PharmacologyT32GM008425 · NIGMS · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI Zeruesenay Desta, Michael Thomas Eadon · 1992 to 2026
$7.7M
EXTRAMURAL RESEARCH FACILITIES IMPROVEMENT: NEUROLOGICAL DISORDERS:ALZ, PDC06RR020128 · NCRR · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI FIFE, ROSE S · 2004 to 2004
$3.7M
MIRA-Regulation of drug metabolizing enzymesR35GM131812 · NIGMS · INDIANA UNIVERSITY INDIANAPOLIS · PI SKAAR, TODD C. · 2019 to 2023
$2.5M
Gene-specific responses to NF-kB through lysine and arginine methylation of p65R01GM120156 · NIGMS · INDIANA UNIVERSITY INDIANAPOLIS · PI LU, TAO · 2017 to 2021
$1.5M
Investigation of the Immune-Mediated Drug-Drug Interaction Potential of Immune Checkpoint InhibitorsK23GM147805 · NIGMS · INDIANA UNIVERSITY INDIANAPOLIS · PI Tyler A Shugg · 2022 to 2026
$836k
Impact of NF-kB methylation on chemoresistance and metastasis of breast cancerR03CA223906 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI LU, TAO, NAKSHATRI, HARIKRISHNA · 2018 to 2019
$157k
NCI NIH HHS R03 CA223906NCRR NIH HHS C06 RR020128NIGMS NIH HHS K23 GM147805NIGMS NIH HHS R01 GM120156NIGMS NIH HHS R35 GM131812NIGMS NIH HHS T32 GM008425
6 · The paper itself

Abstract

Hypertension (HTN) involves genetic variability in the renin-angiotensin system and characterizing this variability will help advance precision antihypertensive treatments. We previously reported that angiotensinogen (

Indexed as

AGTGenetic and Genomic Medicinehypertensionrs699

Identifiers

PMID37066278
PMCPMC10104131
OpenAlexW4362736059

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.